Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
THDBH151
- Development stage
- Phase 2
- Lead developer
- Tonghua Dongbao
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**THDBH151** is an orally administered small-molecule dual inhibitor of xanthine oxidase and urate transporter 1 being developed by Tonghua Dongbao and its subsidiary Dongbao Zixing for gout and hyperuricemia. It lowers serum urate through two complementary mechanisms: inhibition of xanthine oxidase reduces uric acid production, while inhibition of renal urate transporter 1 reduces tubular urate reabsorption and promotes urinary uric acid excretion. The program completed a Phase IIa trial in patients with gout, in which once-daily THDBH151 reduced serum uric acid with a dose-response relationship.
- Other names
- THDBH150/THDBH151
02
Targets
URAT1 (Uric Acid Transporter 1)XO (Xanthine Oxidoreductase)
Beyond the preview
Go deeper on THDBH151.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on THDBH151.